EGFR and non-small cell lung carcinoma: The era of targeted therapies begun in NSCLC with the deployment of the first compounds designed to switch off specific signalling molecules, with a strong focus on aberrant, constitutively active EGFR mutant moieties to arrest oncogenic EGFR-dependent uncontrolled cell proliferation [17,18,20,21,22].